# US 2010/0247568 A1 · Novel adjuvant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247568 A1
- Document ID: US20100247568A1
- Status: Published application
- Kind: A1
- Application number: 12/740,899
- Filed: 2008-10-31
- Published: 2010-09-30
- Earliest claimed: 2007-11-02
- Assignees: Nippon Zenyaku Kogyo Co., Ltd.; Osaka University
- Inventors: Toshihiro Tsukui; Ken Ishii; Shizuo Akira; Cevayir Coban
- Web page: https://patentgrep.com/patent/US20100247568A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/35: Allergens
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/55516: {Proteins; Peptides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method of preventing or treating allergic disease, infectious disease or tumor, which comprises administering a vaccine composition comprising a vaccine adjuvant composition comprising hemozoin or β-hematin in combination with a vaccine selected from the group consisting of an allergen vaccine, an infection vaccine and a tumor vaccine to a subject.

### Claim 26 (depends on 25)

The method according to claim 25, in which the vaccine adjuvant composition comprises 5 μM to 2 mM of hemozoin or β-hematin.

### Claim 27 (depends on 25)

The method according to claim 25, in which the vaccine adjuvant composition is a mucosal vaccine adjuvant.

### Claim 28 (depends on 25)

The method according to claim 25, wherein the allergen is a pollen allergen or a mite allergen, or the infection is an infection due to bacteria or viruses.

### Claim 29

A method of activating dendritic cell, which comprises contacting the dendritic cell with hemozoin or β-hematin.

### Claim 30

A method of preventing or treating allergic disease, infectious disease or tumor, which comprises administering a vaccine composition comprising a vaccine adjuvant composition comprising hemozoin or β-hematin and Alum adjuvant, and vaccine to a subject.

### Claim 31 (depends on 30)

The method according to claim 30, which comprises inducing Th1 immunoreaction.

### Claim 32 (depends on 30)

The method according to claim 30, in which the vaccine composition is a mucosal vaccine.
